Patient characteristics by TERT rare variant status
| . | No TERT rare (n = 1473) . | TERT rare (n = 41) . | P . |
|---|---|---|---|
| Patient-related variables | |||
| Age at transplantation, median (range), y | 59 (0-77) | 52 (14-72) | .03* |
| Female sex, n (%) | 591 (40) | 11 (27) | .11† |
| Karnofsky performance status score <90, n (%) | 403 (27) | 16 (39) | .15† |
| HCT-CI | .15‡ | ||
| 0 | 255 (25) | 3 (11) | |
| 1-2 | 247 (24) | 8 (29) | |
| 3 | 535 (52) | 17 (61) | |
| Missing | 436 | 13 | |
| Disease-related variables | |||
| Hemoglobin, median (IQR), g/dL | 9.4 (8.1-11.2) | 9.9 (8.6-11.1) | .26* |
| Platelet count, median (IQR), ×109/L | 72 (30-147) | 72 (37-115) | .87* |
| Absolute neutrophil count, median (IQR), ×109/L | 1.1 (0.5-2.3) | 1.3 (0.5-2.6) | .63* |
| Bone marrow blasts at transplant, median (IQR), % | 3 (1-6) | 1 (0-5) | .03* |
| Prior MDS-directed therapy, n (%) | 861 (58) | 24 (59) | >.99† |
| Therapy-related MDS, n (%) | 305 (21) | 6 (15) | .43† |
| Myeloid somatic mutations§ | |||
| Present, n (%) | 1,167 (79) | 29 (71) | .24† |
| Absent, n (%) | 306 (21) | 12 (29) | |
| Transplant-related variables | |||
| Conditioning regimen, n (%) | .10† | ||
| Myeloablative | 765 (52) | 24 (59) | |
| Reduced intensity | 565 (39) | 17 (41) | |
| Nonmyeloablative | 130 (9) | 0 (0) | |
| Missing | 13 | 0 | |
| Donor type, n (%) | .85† | ||
| Matched, related | 176 (12) | 5 (12) | |
| Matched, unrelated | 837 (57) | 26 (63) | |
| Mismatched | 289 (20) | 7 (17) | |
| Cord blood | 171 (12) | 3 (7) | |
| Graft type, n (%) | .88† | ||
| Bone marrow | 215 (15) | 6 (15) | |
| Peripheral blood stem cells | 1,082 (73) | 32 (78) | |
| Cord blood | 165 (11) | 3 (7) | |
| Other | 11 (1) | 0 (0) |
| . | No TERT rare (n = 1473) . | TERT rare (n = 41) . | P . |
|---|---|---|---|
| Patient-related variables | |||
| Age at transplantation, median (range), y | 59 (0-77) | 52 (14-72) | .03* |
| Female sex, n (%) | 591 (40) | 11 (27) | .11† |
| Karnofsky performance status score <90, n (%) | 403 (27) | 16 (39) | .15† |
| HCT-CI | .15‡ | ||
| 0 | 255 (25) | 3 (11) | |
| 1-2 | 247 (24) | 8 (29) | |
| 3 | 535 (52) | 17 (61) | |
| Missing | 436 | 13 | |
| Disease-related variables | |||
| Hemoglobin, median (IQR), g/dL | 9.4 (8.1-11.2) | 9.9 (8.6-11.1) | .26* |
| Platelet count, median (IQR), ×109/L | 72 (30-147) | 72 (37-115) | .87* |
| Absolute neutrophil count, median (IQR), ×109/L | 1.1 (0.5-2.3) | 1.3 (0.5-2.6) | .63* |
| Bone marrow blasts at transplant, median (IQR), % | 3 (1-6) | 1 (0-5) | .03* |
| Prior MDS-directed therapy, n (%) | 861 (58) | 24 (59) | >.99† |
| Therapy-related MDS, n (%) | 305 (21) | 6 (15) | .43† |
| Myeloid somatic mutations§ | |||
| Present, n (%) | 1,167 (79) | 29 (71) | .24† |
| Absent, n (%) | 306 (21) | 12 (29) | |
| Transplant-related variables | |||
| Conditioning regimen, n (%) | .10† | ||
| Myeloablative | 765 (52) | 24 (59) | |
| Reduced intensity | 565 (39) | 17 (41) | |
| Nonmyeloablative | 130 (9) | 0 (0) | |
| Missing | 13 | 0 | |
| Donor type, n (%) | .85† | ||
| Matched, related | 176 (12) | 5 (12) | |
| Matched, unrelated | 837 (57) | 26 (63) | |
| Mismatched | 289 (20) | 7 (17) | |
| Cord blood | 171 (12) | 3 (7) | |
| Graft type, n (%) | .88† | ||
| Bone marrow | 215 (15) | 6 (15) | |
| Peripheral blood stem cells | 1,082 (73) | 32 (78) | |
| Cord blood | 165 (11) | 3 (7) | |
| Other | 11 (1) | 0 (0) |
Peripheral blood counts and bone marrow blast counts at time of transplantation.
IQR, interquartile range.
Wilcoxon rank-sum test.
Fisher's exact test.
Cochran-Armitage trend test.
Complete somatic mutations for patients with a TERT rare variants are listed in supplemental Figure 4 and supplemental Table 6.